November 17, 2020 -- The Russian Patent Office has denied a request by Advanced Gene and Cell Technologies (AGCT) to invalidate Factor Bioscience's patent (No. 2,691,027), which covers gene edited hematopoietic cells made using messenger RNA (mRNA).
During the opposition process, consisting of written briefings and several rounds of oral hearings held in front of a board of patent and technology experts, AGCT presented its case, and Factor presented its defense. The Russian Patent Office maintained Factor's patent fully in force.
Factor currently holds more than 90 patents in 14 countries covering foundational technologies in mRNA, gene editing, cell reprogramming, and nucleic acid delivery.
"The successful defense of this patent comes on the heels of our recent U.S. patent covering methods for producing gene-edited cells using mRNA encoding transcription activator-like effector nucleases (TALENs)," said Matt Angel, PhD, co-founder, chairman, and CEO of Factor, in a press release.